glp 1 reduce cancer risk Glucagon-like peptide receptor agonists and risk: the good, the bad and the unknown Glucagon-like peptide 1 receptor agonists

Resetting Dopamine on GLP-1s Heres the thing: Your brain is complicated, and its smarter than you (dont think too hard about that, it gets existential fast)

Potential New Frontiers: Preclinical studies hint at beta-cell protection, improved insulin sensitivity, and a host of other potential benefits that warrant further investigation

According to recent complaints, patients developed non arteritic anterior ischemic optic neuropathy, or NAION, after using the semaglutide based medications

In clinical trials, liraglutide showed a placebo-corrected weight loss of around 5%, semaglutide 12%, and tirzepatide 18% [23]

Thanks for reading The Next Big Think